Novartis pays $150M upfront, including $25M in equity, for Dren Bio’s bispecifics

Dren Bio inked a research pact with Novartis for select myeloid engagers to treat cancer, marking its second collaboration with a large pharma.

The Swiss …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No­var­tis pays $150M up­front, in­clud­ing $25M in eq­ui­ty, for Dren Bio’s bis­pecifics